26815-13-4Relevant academic research and scientific papers
Design and synthesis of benzylpiperidine inhibitors targeting the menin–MLL1 interface
Ren, Jing,Xu, Wei,Tang, Le,Su, Minbo,Chen, Danqi,Chen, Yue-Lei,Zang, Yi,Li, Jia,Shen, Jingkang,Zhou, Yubo,Xiong, Bing
supporting information, p. 4472 - 4476 (2016/08/25)
Menin is an essential oncogenic cofactor for mixed lineage leukemia (MLL)-mediated leukemogenesis, functioning through its direct interaction with MLL1 protein. Therefore, targeting the menin–MLL1 protein–protein interface represents a promising strategy
Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones
Ahn, Gang,Schifano-Faux, Nadège,Goossens, Jean-Fran?ois,Baldeyrou, Brigitte,Couture, Axel,Grandclaudon, Pierre,Lansiaux, Amélie,Ryckebusch, Adina
scheme or table, p. 2259 - 2263 (2011/05/15)
A number of mono- or diaminoalkylated indeno[1,2-c]isoquinolin-5,11-diones analogs of 1 were synthesized and evaluated for their DNA binding affinities, topoisomerase inhibition properties and antiproliferative activities against human cancer cell lines (
Aryl-substituted benzimidazole and imidazopyridine ethers
-
Page/Page column 14, (2010/02/15)
Aryl substituted benzimidazole and imidazo[4,5]pyridine ethers are described as inhibitors of Cds1 and useful as adjuvants to chemotherapy or radiation therapy in the treatment of cancer.
Butenolide endothelin antagonists with improved aqueous solubility
Patt, William C.,Cheng, Xue-Min,Repine, Joseph T.,Lee, Chet,Reisdorph, Bill R.,Massa, Mark A.,Doherty, Annette M.,Welch, Kathleen M.,Bryant, John W.,Flynn, Michael A.,Walker, Donnelle M.,Schroeder, Richard L.,Haleen, Stephen J.,Keiser, Joan A.
, p. 2162 - 2168 (2007/10/03)
Continued development around our ET(A)-selective endothelin (ET) antagonist 1 (CI-1020) has led to the synthesis of analogues with improved aqueous solubility profiles. Poor solubility characteristics displayed by 1 required a complex buffered formulation
CNS active compounds
-
, (2008/06/13)
Compounds of the formula SPC1 Wherein X, R, n and B are as defined herein exhibit antidepressant activity.
